Clinical utility of random anti-tumor necrosis factor drug-level testing and measurement of antidrug antibodies on the long-term treatment response in rheumatoid arthritis

Arthritis and Rheumatology

Volumn 67, Issue 8, 2015, Pages 2011-2019

  Jani, Meghna ^a   Chinoy, Hector ^a   Warren, Richard B ^a   Griffiths, Christopher E M ^a   Plant, Darren ^a   Fu, Bo ^b   Morgan, Ann W ^c   Wilson, Anthony G ^d   Isaacs, John D ^e   Hyrich, Kimmel ^e   Barton, Anne ^a,f  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

^c UNIVERSITY OF LEEDS   (United Kingdom)

^d UNIVERSITY OF SHEFFIELD   (United Kingdom)

^e NEWCASTLE UNIVERSITY   (United Kingdom)

^f UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; DRUG ANTIBODY; ETANERCEPT; GOLD; HYDROXYCHLOROQUINE; LEFLUNOMIDE; METHOTREXATE; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR INHIBITOR; ANTIBODY; ANTIRHEUMATIC AGENT; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY; TNFR-FC FUSION PROTEIN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR;

ADULT; ANTIBODY BLOOD LEVEL; ANTIBODY PRODUCTION; ANTIBODY TITER; ARTICLE; BLOOD SAMPLING; BODY MASS; CLINICAL EVALUATION; COHORT ANALYSIS; CONFIDENCE INTERVAL; CONTROLLED STUDY; DAS28; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE DURATION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SCREENING; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MEASUREMENT; MEDICATION COMPLIANCE; MULTICENTER STUDY; OBSERVATIONAL STUDY; PATIENT SELECTION; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RADIOIMMUNOASSAY; RECEIVER OPERATING CHARACTERISTIC; RHEUMATOID ARTHRITIS; RISK FACTOR; SERUM; TREATMENT DURATION; TREATMENT RESPONSE; AGED; ANTAGONISTS AND INHIBITORS; ARTHRITIS, RHEUMATOID; BLOOD; IMMUNOLOGY; MIDDLE AGED; PROGNOSIS; TREATMENT OUTCOME;

ADULT; AGED; ANTIBODIES; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; COHORT STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; HYDROXYCHLOROQUINE; IMMUNOGLOBULIN G; MALE; METHOTREXATE; MIDDLE AGED; PROGNOSIS; PROSPECTIVE STUDIES; RECEPTORS, TUMOR NECROSIS FACTOR; SULFASALAZINE; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84938118511     PISSN: 23265191     EISSN: 23265205     Source Type: Journal    
DOI: 10.1002/art.39169     Document Type: Article

References (38)

1. Weinblatt ME, Kremer JM, Bankhurst AD, Bulpitt KJ, Fleischmann RM, Fox RI, et al., A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999; 340: 253-9.
2. Weinblatt ME, Keystone EC, Furst DE, Moreland LW, Weisman MH, Birbara CA, et al., Adalimumab, a fully human anti-tumor necrosis factor α monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum 2003; 48: 35-45.
3. Finckh A, Simard JF, Gabay C, Guerne PA., Evidence for differential acquired drug resistance to anti-tumour necrosis factor agents in rheumatoid arthritis. Ann Rheum Dis 2006; 65: 746-52.
4. Radstake TR, Svenson M, Eijsbouts AM, van den Hoogen FH, Enevold C, van Riel PL, et al., Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis. Ann Rheum Dis 2009; 68: 1739-45.
5. Bartelds GM, Krieckaert CL, Nurmohamed MT, van Schouwenburg PA, Lems WF, Twisk JW, et al., Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up. JAMA 2011; 305: 1460-8.
6. Garces S, Demengeot J, Benito-Garcia E., The immunogenicity of anti-TNF therapy in immune-mediated inflammatory diseases: a systematic review of the literature with a meta-analysis. Ann Rheum Dis 2013; 72: 1947-55.
7. Maneiro JR, Salgado E, Gomez-Reino JJ., Immunogenicity of monoclonal antibodies against tumor necrosis factor used in chronic immune-mediated inflammatory conditions: systematic review and meta-analysis. JAMA Intern Med 2013; 173: 1416-28.
8. Paramarta JE, Baeten DL., Adalimumab serum levels and antidrug antibodies towards adalimumab in peripheral spondyloarthritis: no association with clinical response to treatment or with disease relapse upon treatment discontinuation. Arthritis Res Ther 2014; 16: R160.
9. Smolen JS, Landewe R, Breedveld FC, Buch M, Burmester G, Dougados M, et al., EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis 2014; 73: 492-509.
10. Schellekens H., Bioequivalence and immunogenicity of biopharmaceuticals. Nat Rev Drug Discov 2002; 1: 457-62.
11. Jani M, Barton A, Warren RB, Griffiths CE, Chinoy H., The role of DMARDs in reducing the immunogenicity of TNF inhibitors in chronic inflammatory diseases. Rheumatology (Oxford) 2014; 53: 213-22.
12. Hart MH, de Vrieze H, Wouters D, Wolbink GJ, Killestein J, de Groot ER, et al., Differential effect of drug interference in immunogenicity assays. J Immunol Methods 2011; 372: 196-203.
13. Krieckaert CL, Jamnitski A, Nurmohamed MT, Kostense PJ, Boers M, Wolbink G., Comparison of long-term clinical outcome with etanercept treatment and adalimumab treatment of rheumatoid arthritis with respect to immunogenicity. Arthritis Rheum 2012; 64: 3850-5.
14. Bendtzen K, Geborek P, Svenson M, Larsson L, Kapetanovic MC, Saxne T., Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor α inhibitor infliximab. Arthritis Rheum 2006; 54: 3782-9.
15. Potter C, Cordell HJ, Barton A, Daly AK, Hyrich KL, Mann DA, et al., Association between anti-tumour necrosis factor treatment response and genetic variants within the TLR and NFκB signalling pathways. Ann Rheum Dis 2010; 69: 1315-20.
16. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al., The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 315-24.
17. Prevoo ML, van't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL,. Modified disease activity scores that include twenty-eight-joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995; 38: 44-8.
18. Bluett J, Morgan C, Thurston L, Plant D, Hyrich KL, Morgan AW, et al., Impact of inadequate adherence on response to subcutaneously administered anti-tumour necrosis factor drugs: results from the Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate cohort. Rheumatology (Oxford) 2015; 54: 494-9.
19. Van Gestel AM, Prevoo ML, van 't Hof MA, van Rijswijk MH, van de Putte LB, van Riel PL., Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism Criteria. Arthritis Rheum 1996; 39: 34-40.
20. Van Schouwenburg PA, Bartelds GM, Hart MH, Aarden L, Wolbink GJ, Wouters D., A novel method for the detection of antibodies to adalimumab in the presence of drug reveals "hidden" immunogenicity in rheumatoid arthritis patients. J Immunol Methods 2010; 362: 82-8.
21. Sethu S, Govindappa K, Alhaidari M, Pirmohamed M, Park K, Sathish J., Immunogenicity to biologics: mechanisms, prediction and reduction. Arch Immunol Ther Exp (Warsz) 2012; 60: 331-44.
22. Aalberse RC, Stapel SO, Schuurman J, Rispens T., Immunoglobulin G4: an odd antibody. Clin Exp Allergy 2009; 39: 469-77.
23. Jamnitski A, Krieckaert CL, Nurmohamed MT, Hart MH, Dijkmans BA, Aarden L, et al., Patients non-responding to etanercept obtain lower etanercept concentrations compared with responding patients. Ann Rheum Dis 2012; 71: 88-91.
24. Hoshino M, Yoshio T, Onishi S, Minota S., Influence of antibodies against infliximab and etanercept on the treatment effectiveness of these agents in Japanese patients with rheumatoid arthritis. Mod Rheumatol 2012; 22: 532-40.
25. Pouw MF, Krieckaert CL, Nurmohamed MT, van der Kleij D, Aarden L, Rispens T, et al., Key findings towards optimising adalimumab treatment: the concentration-effect curve. Ann Rheum Dis 2015; 74: 513-8.
26. Vincent FB, Morand EF, Murphy K, Mackay F, Mariette X, Marcelli C., Antidrug antibodies (ADAb) to tumour necrosis factor (TNF)-specific neutralising agents in chronic inflammatory diseases: a real issue, a clinical perspective. Ann Rheum Dis 2013; 72: 165-78.
27. Van der Laken CJ, Voskuyl AE, Roos JC, Stigter van Walsum M, de Groot ER, Wolbink G, et al., Imaging and serum analysis of immune complex formation of radiolabelled infliximab and anti-infliximab in responders and non-responders to therapy for rheumatoid arthritis. Ann Rheum Dis 2007; 66: 253-6.
28. Van Schouwenburg PA, van de Stadt LA, de Jong RN, van Buren EE, Kruithof S, de Groot E, et al., Adalimumab elicits a restricted anti-idiotypic antibody response in autoimmune patients resulting in functional neutralisation. Ann Rheum Dis 2013; 72: 104-9.
29. Bendtzen K., Is there a need for immunopharmacologic guidance of anti-tumor necrosis factor therapies? Arthritis Rheum 2011; 63: 867-70.
30. Jamnitski A, Bartelds GM, Nurmohamed MT, van Schouwenburg PA, van Schaardenburg D, Stapel SO, et al., The presence or absence of antibodies to infliximab or adalimumab determines the outcome of switching to etanercept. Ann Rheum Dis 2011; 70: 284-8.
31. Krieckaert CL, Nurmohamed MT, Wolbink GJ., Methotrexate reduces immunogenicity in adalimumab treated rheumatoid arthritis. Ann Rheum Dis 2012; 71: 1914-5.
32. De Vries MK, van der Horst-Bruinsma IE, Nurmohamed MT, Aarden LA, Stapel SO, Peters MJ, et al., Immunogenicity does not influence treatment with etanercept in patients with ankylosing spondylitis. Ann Rheum Dis 2009; 68: 531-5.
33. Klareskog L, Gaubitz M, Rodriguez-Valverde V, Malaise M, Dougados M, Wajdula J., Assessment of long-term safety and efficacy of etanercept in a 5-year extension study in patients with rheumatoid arthritis. Clin Exp Rheumatol 2011; 29: 238-47.
34. Keystone EC, Schiff MH, Kremer JM, Kafka S, Lovy M, DeVries T, et al., Once-weekly administration of 50 mg etanercept in patients with active rheumatoid arthritis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2004; 50: 353-63.
35. Dore RK, Mathews S, Schechtman J, Surbeck W, Mandel D, Patel A, et al., The immunogenicity, safety, and efficacy of etanercept liquid administered once weekly in patients with rheumatoid arthritis. Clin Exp Rheumatol 2007; 25: 40-6.
36. Kneepkens EL, Krieckaert CL, van der Kleij D, Nurmohamed MT, van der Horst-Bruinsma IE, Rispens T, et al., Lower etanercept levels are associated with high disease activity in ankylosing spondylitis patients at 24 weeks of follow-up. Ann Rheum Dis 2014. E-pub ahead of print.
37. Mahil SK, Arkir Z, Richards G, Lewis CM, Barker JN, Smith CH., Predicting treatment response in psoriasis using serum levels of adalimumab and etanercept: a single centre, cohort study. Br J Dermatol 2013; 169: 306-13.
38. Tilg H, Moschen AR., Adipocytokines: mediators linking adipose tissue, inflammation and immunity. Nat Rev Immunol 2006; 6: 772-83.